Advanced in Lung Metastases

Sabine M. Schmid

Bern, BE, CH 
Advanced in Lung Metastases
Bern, BE, CH 
OverviewLocationsClinical Research

Overview

Sabine Schmid practices in Bern, Switzerland. Ms. Schmid is rated as an Advanced expert by MediFind in the treatment of Lung Metastases. Her top areas of expertise are Lung Cancer, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Lung Metastases.

Gender
Female

Locations

Bern, BE, Switzerland
Other Locations
Cantonal Hospital St. Gallen
Sankt Gallen, SG, Switzerland
Kantonsspital St Gallen, St Gallen
Switzerland
Zurich, ZH 8001, Switzerland
Basel, BS 4031, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 3
View 1 Less Clinical Trial

77 Total Publications

ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Schmid's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile